Publications of Peter L. Perrotta, MD

Seven Q-Tracks monitors of laboratory quality drive general performance improvement: experience from the College of American Pathologists Q-Tracks program 1999-2011.
Meier FA, Souers RJ, Howanitz PJ, Tworek JA, Perrotta PL, Nakhleh RE, Karcher DS, Bashleben C, Darcy TP, Schifman RB, Jones BA.
Arch Pathol Lab Med. 2015;139(6):762-775.


Twenty-five years of accomplishments of the college of american pathologists q-probes program for clinical pathology.
Howanitz PJ, Perrotta PL, Bashleben CP, Meier FA, Ramsey GE, Massie LW, Zimmerman RL, Karcher DS.
Arch Pathol Lab Med. 2014;138(9):1141-1149.


Frequency monitoring of hemoglobin a1c, low-density lipoprotein, and urine protein laboratory testing: a college of american pathologists q-probes study.
Perrotta PL, Jones R, Souers RJ, Darcy TP, Howanitz PJ.
Arch Pathol Lab Med. 2014;138(8):1009-1014.


Abbott ARCHITECT iPhenytoin assay versus similar assays for measuring free phenytoin concentrations.
Tacker DH, Robinson R, Perrotta PL.
Lab Med. 2014;45(2):176-181.


Workflow analysis comparing manual and automated specimen processing for mass spectrometry-based vitamin d testing.
Tacker DH, Topardo J, Mahaffey C, Perrotta PL.
Lab Med. 2014;45(4):361-367.


Abbott ARCHITECT iPhenytoin assay versus similar assays for measuring free phenytoin concentrations.
Tacker DH, Robinson R, Perrotta PL.
Labmedicine. 2014;45(2):176-181.


Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens.
LaSala PR, Ekhmimi T, Hill AK, Farooqi I, Perrotta PL.
J Clin Microbiol. 2013;51(1):311-313.

PMC3536223.

Comparison of analytical and clinical performance of three methods for detection of Clostridium difficile.
LaSala PR, Svensson AM, Mohammad AA, Perrotta PL.
Arch Pathol Lab Med. 2012;136(5):527-531.


Pulmonary particulate matter and systemic microvascular dysfunction.
Nurkiewicz TR, Porter DW, Hubbs AF, Stone S, Moseley AM, Cumpston JL, Goodwill AG, Frisbee SJ, Perrotta PL, Brock RW, Frisbee JC, Boegehold MA, Frazer DG, Chen BT, Castranova V, HEI Health Review Committee.
Res Rep Health Eff Inst. 2011;(164):3-48.


Fit-for-purpose evaluation of architect i1000SR immunoassay analyzer.
Rukhsana J, Perrotta PL, Okorodudu AO, Petersen JR, Mohammad AA.
Clin Chim Acta. 2010;411(11-12):798-801.


Molecular diagnostics in hemostatic disorders.
Perrotta PL, Svensson AM.
Clin Lab Med. 2009;29(2):367-390.


Proteomics: moving from a discovery to a quality assurance tool.
Perrotta PL.
Transfusion (Paris). 2008;48(3):408-410.


Proteomic approaches to dissect platelet function: Half the story.
Gnatenko DV, Perrotta PL, Bahou WF.
Blood. 2006;108(13):3983-3991.

PMC1895451.

Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype.
Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF.
Thromb Haemost. 2005;94(2):412-421.


Proteomics in platelet science.
Perrotta PL, Bahou WF.
Curr Hematol Rep. 2004;3(6):462-469.


Proteomics in transfusion medicine.
Reddy KS, Perrotta PL.
Transfusion (Paris). 2004;44(4):601-604.


Transcript profiling of human platelets using microarray and serial analysis of gene expression.
Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF.
Blood. 2003;101(6):2285-2293.


Platelet activation in a circulating flow loop: combined effects of shear stress and exposure time.
Jesty J, Yin W, Perrotta PL, Bluestein D.
Platelets. 2003;14(3):143-149.


Apoptotic activity in stored human platelets.
Perrotta PL, Perrotta CL, Snyder EL.
Transfusion (Paris). 2003;43(4):526-535.


Applying a novel statistical process control model to platelet quality monitoring.
Perrotta PL, Ozcan C, Whitbread JA, Finch SJ.
Transfusion (Paris). 2002;42(8):1059-1066.


Non-infectious complications of transfusion therapy.
Perrotta PL, Snyder EL.
Blood Rev. 2001;15(2):69-83.


Integration of a hematopoietic progenitor cell program using the ACT/DB database system.
Perrotta PL, Nadkarni PM.
Comput Methods Programs Biomed. 2000;61(3):195-207.


Effects of methylene blue-treated plasma on red cells and stored platelet concentrates.
Perrotta PL, Baril L, Tead C, Chapman J, Dincecco D, Buchholz DH, Snyder EL.
Transfusion (Paris). 1999;39(1):63-69.


Inducible nitric oxide synthase with transitional cell carcinoma of the bladder.
Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM.
J Urol. 1999;161(2):630-634.


Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence.
Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, Carter D, Kacinski BM, Haffty BG.
Clin Cancer Res. 1998;4(8):1851-1856.


Liesegang rings and endometriosis.
Perrotta PL, Ginsburg FW, Siderides CI, Parkash V.
Int J Gynecol Pathol. 1998;17(4):358-362.


Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody.
Flick MB, Sapi E, Perrotta PL, Maher MG, Halaban R, Carter D, Kacinski BM.
Oncogene. 1997;14(21):2553-2561.


Removal of anaphylatoxins C3a and C5a and chemokines interleukin 8 and RANTES by polyester white cell-reduction and plasma filters.
Geiger TL, Perrotta PL, Davenport R, Baril L, Snyder EL.
Transfusion (Paris). 1997;37(11-12):1156-1162.


Effects of the submarine environment on renal-stone risk factors and vitamin D metabolism.
Dlugos DJ, Perrotta PL, Horn WG.
Undersea Hyperb Med. 1995;22(2):145-152.


The efficacy of the placental biopsy.
Kliman HJ, Perrotta PL, Jones DC.
Am J Obstet Gynecol. 1995;173(4):1084-1088.


Treatment of carbon monoxide poisoning: a critical review of human outcome studies comparing normobaric oxygen with hyperbaric oxygen.
Tibbles PM, Perrotta PL.
Ann Emerg Med. 1994;24(2):269-276.